A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:37
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
[21]   Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus [J].
Liakos, Aris ;
Karagiannis, Thomas ;
Bekiari, Eleni ;
Boura, Panagiota ;
Tsapas, Apostolos .
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (02) :61-67
[22]   Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial [J].
Ferreira, Juan C. Arjona ;
Corry, Dalila ;
Mogensen, Carl E. ;
Sloan, Lance ;
Xu, Lei ;
Golm, Gregory T. ;
Gonzalez, Edward J. ;
Davies, Michael J. ;
Kaufman, Keith D. ;
Goldstein, Barry J. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (04) :579-587
[23]   The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study [J].
Takihata, Masahiro ;
Terauchi, Yasuo .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (17) :2185-2194
[24]   Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial [J].
Kothny, Wolfgang ;
Lukashevich, Valentina ;
Foley, James E. ;
Rendell, Marc S. ;
Schweizer, Anja .
DIABETOLOGIA, 2015, 58 (09) :2020-2026
[25]   Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials [J].
Jabbour, Serge ;
Seufert, Jochen ;
Scheen, Andre ;
Bailey, Clifford J. ;
Karup, Cathrina ;
Langkilde, Anna M. .
DIABETES OBESITY & METABOLISM, 2018, 20 (03) :620-628
[26]   Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia [J].
Fukuda, Masahiro ;
Doi, Kunihiro ;
Sugawara, Masahiro ;
Mochizuki, Koichi .
JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (02) :383-391
[27]   Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus: a meta-analysis [J].
Zhao, Jun-Yu ;
Wang, Hai-Peng ;
Wang, Huan-Jun ;
Yao, Jin-Ming ;
Wu, Xiao-Yun ;
Dong, Jian-Jun ;
Liao, Lin .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06) :11202-11210
[28]   Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus [J].
Scheen, Andre J. ;
Charpentier, Guillaume ;
Ostgren, Carl Johan ;
Hellqvist, Asa ;
Gause-Nilsson, Ingrid .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (07) :540-549
[29]   Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial [J].
Charbonnel, B. ;
Steinberg, H. ;
Eymard, E. ;
Xu, L. ;
Thakkar, P. ;
Prabhu, V. ;
Davies, M. J. ;
Engel, S. S. .
DIABETOLOGIA, 2013, 56 (07) :1503-1511
[30]   Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial [J].
Zang, L. ;
Liu, Y. ;
Geng, J. ;
Luo, Y. ;
Bian, F. ;
Lv, X. ;
Yang, J. ;
Liu, J. ;
Peng, Y. ;
Li, Y. ;
Sun, Y. ;
Bosch-Traberg, H. ;
Mu, Y. .
DIABETES OBESITY & METABOLISM, 2016, 18 (08) :803-811